Company
AffiPCR Biosystems was founded in 2015 to develop next-generation PCR reagents. Our molecular evolution technology platform is currently being used to optimize enzymes for DNA amplification, next-generation DNA sequencing, and molecular diagnostic applications.
The majority of biomedical and research applications were designed around a small subset of native enzymes. The limitations of these applications are often the result of constraints due to enzyme structure or function. Recent advances in molecular evolution have allowed enzymes to be tailored to suit specific application requirements. Enzyme engineering improves existing methods and provides the foundation on which entirely novel applications can be built.
AffiPCR Biosystems conducts advanced protein engineering, taking advantage of recent developments in genomics, proteomics, and synthetic biology.
The AffiPCR Team
The AffiPCR Biosystems team combines a strong balance of scientific and commercial expertise. Our world-class team of scientists is led by Chief Scientific Officer, developing breakthrough biochemistry and instrumentation in the field of high-throughput genomics including: inventing technologies and automation for the Human Genome Project at the Whitehead Institute Center for Genomic Research leading to the co-founding of genomics companies Agencourt Bioscience and Agencourt Personal Genomics.
At Affigen our vision is to invent, engineer, and deliver biotechnology solutions that empower our customers to shape the present and future of life science.
